Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Incidence of vulvar high-grade precancerous lesions and cancer in Denmark before and after introduction of HPV vaccination

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Non-epithelial ovarian cancer in Denmark - Incidence and survival over nearly 40 years

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Jammbe Z Musoro
  • Corneel Coens
  • Elfriede Greimel
  • Madeleine T King
  • Mirjam A G Sprangers
  • Andy Nordin
  • Eleonora B L van Dorst
  • Mogens Groenvold
  • Kim Cocks
  • Galina Velikova
  • Hans-Henning Flechtner
  • Andrew Bottomley
Vis graf over relationer

INTRODUCTION: Minimal important differences (MIDs) are useful for interpreting changes or differences in health-related quality of life scores in terms of clinical importance. There are currently no MID guidelines for the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire core 30 (EORTC QLQ-C30) specific to ovarian cancer. This study aims to estimate MIDs for interpreting group-level change of EORTC QLQ-C30 scores in ovarian cancer.

METHODS: Data were derived from four EORTC published trials. Clinical anchors for each EORTC QLQ-C30 scale were selected using correlation strength and clinical plausibility. MIDs for within-group change and between-group differences in change over time were estimated via mean change method and linear regression respectively. For each EORTC QLQ-C30 scale, MID estimates from multiple anchors were summarized via weighted-correlation. Distribution-based MIDs were also examined as supportive evidence.

RESULTS: Anchor-based MIDs were determined for deterioration in 7 of the 14 EORTC QLQ-C30 scales assessed, and in 11 scales for improvement. Anchor-based MIDs for within-group change ranged from 4 to 19 (improvement) and - 9 to -4 (deterioration). Between-group MIDs ranged from 3 to 13 (improvement) and - 11 to -4 (deterioration). Generally, absolute anchor-based MIDs for most scales ranged from 4 to 10 points.

CONCLUSIONS: Our findings will aid interpretation of EORTC QLQ-C30 scores in ovarian cancer and inform sample size calculations in future ovarian cancer trials with endpoints that are based on EORTC QLQ-C30 scales.

OriginalsprogEngelsk
TidsskriftGynecologic Oncology
Vol/bind159
Udgave nummer2
Sider (fra-til)515-521
Antal sider7
ISSN0090-8258
DOI
StatusUdgivet - nov. 2020

Bibliografisk note

Copyright © 2020 Elsevier Inc. All rights reserved.

ID: 61155283